CDH2 and neoplasm: Unlike prior EMT-focused studies that conceptualize cisplatin resistance as a uniform mesenchymal state, our single-cell RNA sequencing analysis reveals that CDH2 expression is selectively enriched in specific resistant tumor subpopulations rather than uniformly across all malignant cells.